Digital Content 
NEWS #PharmaBuzz
13 Apr 2026
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/ideaya-eye-cancer-drug-meets-main-goal-mid-to-late-stage-trial-2026-04-13/
13 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a0201-negative-metastatic-uveal-melanoma-302739905.html
13 Apr 2026
// BIOSPACE
https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy
11 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-to-announce-topline-results-from-phase-23-optimum-02-trial-in-metastatic-uveal-melanoma-on-monday-april-13-2026-302739365.html
30 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib--crizotinib-combination-in-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302542236.html
31 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-302415020.html
Share